4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2% – Time to Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose 6.2% during trading on Wednesday . The company traded as high as $10.98 and last traded at $10.7150. Approximately 426,187 shares traded hands during trading, a decline of 50% from the average daily volume of 857,576 shares. The stock had previously closed at $10.09.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Roth Capital decreased their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Finally, Barclays lowered their price objective on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Stock Up 6.5%

The firm has a fifty day moving average of $9.46 and a 200-day moving average of $6.40. The firm has a market cap of $613.92 million, a P/E ratio of -2.86 and a beta of 2.96.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. Sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the transaction, the insider directly owned 3,594 shares of the company’s stock, valued at approximately $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 9,128 shares of company stock valued at $92,100 over the last quarter. 9.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $39,000. Y Intercept Hong Kong Ltd acquired a new position in 4D Molecular Therapeutics in the first quarter valued at about $41,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics during the third quarter worth about $41,000. Los Angeles Capital Management LLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $42,000. Finally, Quadrature Capital Ltd bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at about $42,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.